Sandoz Of Novartis AG (NYSE:NVS) Acquires Antibiotics Of GlaxoSmithKline Plc (NYSE:GSK) For $500 Million

Novartis AG (NYSE:NVS)’s Sandoz entered a deal with GlaxoSmithKline Plc (NYSE:GSK) to acquire the established antibiotic brands like Fortum, Zinacef, and Zinnat for $350 million. GlaxoSmithKline will also receive milestone payments of up to $150 million. The deal will be closed by the end of this year. Sandoz decided to purchase antibiotics brands after it […]

Novartis (NYSE:NVS) Enters Agreement For Manufacture Of Pfizer Inc. (NYSE:PFE) And BioNTech’s (NASDAQ:BNTX) mRNA Vaccine

Novartis (NYSE:NVS) has entered an initial agreement with Pfizer Inc. (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX) for manufacturing support to boost production of their mRNA COVID-19 vaccine to help address supply shortages. This is an example of an unlikely collaboration between big pharmaceutical companies geared at the fight against the coronavirus pandemic. Novartis signs vaccine manufacturing […]

Novartis AG (NYSE:NVS) Reports First REACH3 Study Data Showing Jakavi®’s Improving Patients Outcomes In chronic GvHD

Novartis AG (NYSE:NVS) has announced its third phase REACH3 study results, which showed that Jakavi® significant failure-free survival improvements in patients with steroid-refractory chronic graft-versus-host disease (GvHD) relative to best available therapy (BAT). Novartis reports positive REACH3 results of Jakavi in chronic GvHD The company presented the REACH3 results at the Annual 62nd American Society […]

Novartis AG (NYSE:NVS) Fires Leading Scientists Over Claims Of Gene Therapy Data Manipulation

The gene therapy division of Novartis AG (NYSE:NVS) will be missing the services of two of the company’s top scientists. Brian Kaspar and Allan Kaspar are the exiting scientists. Novartis decided to fire them after it learnt that they were involved in manipulation of gene therapy data. The Kaspars scandal The company’s CEO, Vas Narasimhan, […]

Novartis AG (NYSE:NVS) Announces New Clinical Study Updates at the ASCO 2019 Meeting

Novartis AG (NYSE:NVS) posted new clinical study updates in NSCLC at the recently held ASCO 2019 Annual Meeting. This comprised primary efficacy data from the GEOMETRY mono-1 Phase 2 clinical study. It showed that INC280 comes as a potential treatment alternative for subjects with metastatic or locally advanced NSCLC that has MET exon-14 skipping mutation. […]

Impact Of Billion Dollar Deal Between Celgene Corporation (NASDAQ:CELG) And Juno Therapeutics Inc (NASDAQ:JUNO) On Biotech Market

Celgene Corporation (NASDAQ:CELG) announced yesterday that it will spend roughly $1 billion to venture into a partnership with Juno Therapeutics Inc (NASDAQ:JUNO). The two firms will engage in a ten-year partnership that is expected to keep the biotech bull market going. Celgene maintains that the deal is in the best interest of the company, regardless […]

GlaxoSmithKline plc (ADR) (NYSE:GSK) Bankrolls A Tiny Startup In Search Of An HIV Cure

GlaxoSmithKline plc (ADR) (NYSE:GSK) will team up with the University of North Carolina to form a spinoff that will initially put all its focus on the search for a cure for HIV. The company has been experiencing some rough times and will allocate some of its resources to the joint venture that it hopes will […]

Eli Lilly and Co (NYSE:LLY) Opens a Facility At Cambridge

Eli Lilly and Co (NYSE:LLY) is looking to Cambridge to jump start its innovation engine. The company will be building a new R&D facility on the Charles River becoming the latest company to make the move. The new facility is named Lilly Cambridge Innovation Center and will start by the end of the year Kendall […]

GlaxoSmithKline Plc (ADR) (NYSE:GSK) Unveils Big Business Growth Targets

On Wednesday, GlaxoSmithKline plc (ADR) (NYSE:GSK) divulged its growth goals. This is an endeavor to persuade investors that concentrating on consumer health and vaccines would bring back long-term growth. It also discarded plans to float its HIV drug business ViiV Healthcare pointing to its strong outlook. Further, it pledged to disburse a regular dividend of […]

Novartis AG’s (ADR) (NYSE:NVS) (ADR) Looking For Buyout in the Range of $2 billion to $5 billion

Novartis AG’s (ADR) (NYSE:NVS) CEO Joe Jimenez is looking for a buyout in the range of $2 billion to $5 billion. The news comes a month after Novartis completed its big asset swap with GlaxoSmithKline plc (NYSE:GSK). Mr. Jimenez stated that the company has put the mergers and acquisition people back to work. The company is […]

FDA Clears The Way For Arrowhead Research Corp (NASDAQ:ARWR) Hep B Treatment, With A Caveat

Arrowhead Research Corp (NASDAQ:ARWR) has finally been given the go ahead sign to beggin its phase II B trials of ARC 520. The company will now be able to further its research on the Hepatitis B treatment courtesy of the FDA. Despite the approval, the company still has to persuade other supervisory bodies before it […]

Novartis AG (ADR)(NYSE:NVS) Drug Signifor LAR To Be Used For Treating Patients With Rare Hormonal Disorder Acromegaly

Boston, MA 09/29/2014 (wallstreetpr) – According to reports, Novartis AG (ADR)(NYSE:NVS)‘s drug Signifor LAR has got the recommendation of CHMP for the approval of EU. It can be used to cure patients that suffer from Acromegaly; a rare hormonal disorder. Insights about Acromegaly: As per the reports, it is an endocrine disorder, which is normally caused […]

CEO Alan Shortall Talks On Unilife Corp (NASDAQ:UNIS) 4Q2014 Results

Boston, MA 09/11/2014 (wallstreetpr) – Alan Shortall, Chairman and the CEO of Unilife Corp (NASDAQ:UNIS) discussed the fourth quarter results on a conference call held on Wednesday. Shortall started the talks on the positive note as he said that the management is delighted with the trajectory of the business. Unilife is well positioned to deliver […]

Receptos Inc (NASDAQ:RCPT) Raising Funds For Product Development

Boston, MA 06/19/2014 (wallstreetpr) – Receptos Inc (NASDAQ:RCPT) has turned to equity offering to raise funds for the development of its lead drug candidate PRC1063 and others. The drug is going through Phase III trial after showing compelling results in its Phase II study. The treatment targets multiple sclerosis (MS). The company has announced offering of […]

Glaxo SmithKline plc (ADR) (NYSE:GSK) Strikes Deal On Cancer Drug Venture

Boston, MA 06/04/2014 (wallstreetpr) – Developer and manufacturer of global healthcare products, Glaxo SmithKline plc (ADR) (NYSE:GSK) has struck a deal with biotechnology and privately-held company, Adaptimmune, for the development of a drug for cancer. Cancer Drug Glaxo SmithKline’s deal with Adaptimmune is reportedly worth over $350 million that is spread over a period of […]